Direct Biologics

Exosome/regenerative therapy (private)

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
MSC-derived exosomesCell therapy
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
June 2027 (1)
ExoFloPhase 2Crohn Disease (CD)
Est. primary completion 2027-06 · NCT07625293 · CT.gov ↗
What to watch
July 2027 (1)
ExoFloPhase 2Perianal Fistula Due to Crohn's Disease
Est. primary completion 2027-07-30 · NCT06918808 · CT.gov ↗
What to watch
November 2027 (1)
ExoFloPhase 3Acute Respiratory Distress Syndrome, ARDS
Est. primary completion 2027-11-30 · NCT05354141 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.